A potential solution for the shortage of donors in islet transplantation using a novel oral antidiabetic agent, troglitazone.
Nagai
T
T
First Department of Surgery, Fukuoka University School of Medicine, Japan.
Yasunami
Y
Y
Nagata
N
N
Ryu
S
S
Ono
J
J
Ikeda
S
S
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002452:Cell Count; D002839:Chromans / Q000008:administration & dosage / Q000494:pharmacology*; D003131:Combined Modality Therapy; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy / Q000601:surgery; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016381:Islets of Langerhans Transplantation / Q000379:methods* / Q000502:physiology; D051381:Rats; D011917:Rats, Inbred Lew; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology*; D045162:Thiazolidinediones; D014185:Transplantation, Isogeneic; D000077288:Troglitazone
D001786:Blood Glucose; D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone